NO117626B - - Google Patents
Download PDFInfo
- Publication number
- NO117626B NO117626B NO16911467A NO16911467A NO117626B NO 117626 B NO117626 B NO 117626B NO 16911467 A NO16911467 A NO 16911467A NO 16911467 A NO16911467 A NO 16911467A NO 117626 B NO117626 B NO 117626B
- Authority
- NO
- Norway
- Prior art keywords
- vaccine
- poliomyelitis
- virus
- potential
- vaccines
- Prior art date
Links
- 241000700605 Viruses Species 0.000 claims description 40
- 208000000474 Poliomyelitis Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 18
- 229960001539 poliomyelitis vaccine Drugs 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 238000003860 storage Methods 0.000 description 13
- 239000013068 control sample Substances 0.000 description 7
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 7
- 229940033663 thimerosal Drugs 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100388690 Plasmodium falciparum (isolate K1 / Thailand) MEF-1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- TWJVNKMWXNTSAP-UHFFFAOYSA-N azanium;hydroxide;hydrochloride Chemical compound [NH4+].O.[Cl-] TWJVNKMWXNTSAP-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940100892 mercury compound Drugs 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C06—EXPLOSIVES; MATCHES
- C06B—EXPLOSIVES OR THERMIC COMPOSITIONS; MANUFACTURE THEREOF; USE OF SINGLE SUBSTANCES AS EXPLOSIVES
- C06B25/00—Compositions containing a nitrated organic compound
- C06B25/18—Compositions containing a nitrated organic compound the compound being nitrocellulose present as 10% or more by weight of the total composition
- C06B25/20—Compositions containing a nitrated organic compound the compound being nitrocellulose present as 10% or more by weight of the total composition with a non-explosive or a non-explosive or a non-thermic component
-
- C—CHEMISTRY; METALLURGY
- C06—EXPLOSIVES; MATCHES
- C06B—EXPLOSIVES OR THERMIC COMPOSITIONS; MANUFACTURE THEREOF; USE OF SINGLE SUBSTANCES AS EXPLOSIVES
- C06B23/00—Compositions characterised by non-explosive or non-thermic constituents
- C06B23/002—Sensitisers or density reducing agents, foam stabilisers, crystal habit modifiers
- C06B23/004—Chemical sensitisers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DED0050669 | 1966-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO117626B true NO117626B (zh) | 1969-09-01 |
Family
ID=7052828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO16911467A NO117626B (zh) | 1966-07-23 | 1967-07-20 |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE701725A (zh) |
| DE (1) | DE1571218A1 (zh) |
| GB (1) | GB1170695A (zh) |
| NL (1) | NL6710138A (zh) |
| NO (1) | NO117626B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2193491B (en) * | 1978-07-21 | 1988-09-14 | Imi Kynoch Limited Kynoch Work | Improvements in propellants |
| GB2246348B (en) * | 1986-07-15 | 1993-03-03 | Ici Plc | Nitrocellulose propellant composition |
| DE19907809C2 (de) * | 1999-02-24 | 2002-10-10 | Nitrochemie Gmbh | Verfahren zur Herstellung von ein-, zwei- oder dreibasigen Triebladungspulvern für Rohrwaffenmunition |
-
1966
- 1966-07-23 DE DE19661571218 patent/DE1571218A1/de active Pending
-
1967
- 1967-07-20 NO NO16911467A patent/NO117626B/no unknown
- 1967-07-21 NL NL6710138A patent/NL6710138A/xx unknown
- 1967-07-21 GB GB3378267A patent/GB1170695A/en not_active Expired
- 1967-07-24 BE BE701725D patent/BE701725A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE1571218A1 (de) | 1970-11-26 |
| GB1170695A (en) | 1969-11-12 |
| NL6710138A (zh) | 1968-01-24 |
| BE701725A (zh) | 1968-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koch et al. | Quantitative Studies on the Infectivity of ribonucleic acid from partially purified and highly purified poliovirus preparations | |
| Rivers | Cultivation of vaccine virus for Jennerian prophylaxis in man | |
| Conant et al. | Rhinoviruses: Basis for a Numbering System: 1. HeLa Cells for Propagation and Serologic Procedures | |
| US3520972A (en) | Feline virus vaccines obtained by propagation and serial passage attenuation of virulent feline viruses in diploid feline embryo tissue cell serial passage subculture strains | |
| Yanamura et al. | Studies on the virus of psittacosis cultivated in vitro | |
| Brown et al. | The" toxic" activity of vaccinia virus in tissue culture | |
| Gugerell et al. | Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine | |
| Gwaltney Jr | Micro-neutralization test for identification of rhinovirus serotypes. | |
| Collier | The preservation of vaccinia virus | |
| Sullivan et al. | Thermal resistance of certain oncogenic viruses suspended in milk and milk products | |
| NO117626B (zh) | ||
| Drake et al. | Effect of nitrogen mustard on virus of serum hepatitis in whole blood. | |
| EP0011864A1 (en) | Attenuated strain of feline infectious peritonitis virus, method for preparing it and vaccine comprising it | |
| US3709782A (en) | Heteroploid cell lines | |
| US2793160A (en) | Poliomyelitis vaccine | |
| US3097140A (en) | Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride | |
| RU2290205C1 (ru) | Способ получения живой вакцины для профилактики гриппа | |
| CN1468091A (zh) | 疫苗组合物和稳定化的方法 | |
| US4021302A (en) | Cell cultures | |
| Gardner et al. | Transformation of rabbit fibroma virus (Shope) into infectious myxomatosis (Sanarelli) | |
| CN107475204A (zh) | 一种囊膜病毒保护剂及其制备方法 | |
| US2705696A (en) | Production of antigens | |
| McGAVING | Inactivation of canine parvovirus by disinfectants and heat | |
| US4886779A (en) | Inactivation of human immunodeficiency virus (HIV) in protein-containing solutions by phenols | |
| US6403363B1 (en) | Method of preservation of vaccines with polybiguanide |